Zoetis inks $255M deal for Abbott's animal health biz; Pfizer cancer pact dampens investors' AZ hopes;

@FiercePharma: Kindred's losses expand as struggling startup boosts R&D efforts. More | Follow @FiercePharma

@CarlyHFierce: $ACT to Acquire Allergan to Create Top 10 Global Growth Pharmaceutical Company with $23 Billion in Revenue. Release | Follow @CarlyHFierce

> Zoetis ($ZTS)--which recently adopted a poison pill defense after activist investor Bill Ackman acquired an 8.5% stake in the company--has agreed to buy Abbott's ($ABT) animal health business for $255 million. Release | More

> A major cancer deal between Pfizer ($PFE) and Merck KGaA has dampened investors' hopes that the New York drug giant will make another run at AstraZeneca ($AZN). Story

> After a disappointing forecast for its diabetes business and the ousting of its CEO, Sanofi ($SNY) has resumed share repurchasing for the first time since July. Report

> Baring Private Equity Asia has agreed to acquire Japan's Bushu Pharma for $670 million. Report

Medical Device News

@FierceMedDev: UPDATED w/ info from @AdvaMedUpdate Trade agreement with China paves the way for reduction in medical device tariffs. Article | Follow @FierceMedDev

@EmilyWFierce: Reckitt ready to set pharma free in December spinoff, dubbed Indivior. Story | Follow @EmilyWFierce

> Medtronic partners with DaVita as it rolls out CRT meta-analysis data. Story

> LifeBond raising $25M to support development of surgical sealant technology. More

> Report: Hold off on knee replacement until it's necessary. Article

Biotech News

@FierceBiotech: Buzz: Actavis closes in on Big Pharma status with $64B Allergan buyout. Report | Follow @FierceBiotech

@JohnCFierce: Buzz is on. It looks like Allergan found its White Knight deal in Actavis. More likely that Pfizer now follows up? | Follow @JohnCFierce

@DamianFierce: Relevant to today's $PFE + Merck KGaA deal: @FierceBiotech's (now dated) list of the biggest upfront payments ever. More | Follow @DamianFierce

> Actavis bags top 10 Big Pharma status with $66B Allergan buyout. Story

> Bristol-Myers adds to impressive Opdivo survival data with PhIII melanoma results. More

> AstraZeneca's PhIII gout data for lesinurad includes a hit, a strikeout and a missing player. Story

> FDA reverses an embarrassing rejection of Sanofi's Lemtrada, OKs MS drug. Article

CRO News

> Recipharm trades $140M for a Portuguese CDMO. Story

> Catalent makes another buy and ticks up its revenue. Report

> Parexel eyes logistics with latest EU expansion. Story

> WuXi ups its revenue ambitions after M&A and expansion. Article

Biotech IT News

> Pathway Genomics strikes IBM Watson deal and research collaboration. Report

> Ombudsman pushes EMA for explanation of Humira CSR redactions. Item

> Venter's HLI inks deal to access registry of 11,000 twins. Story

> Genomics England seeks teams to analyze data from 100,000 Genomes Project. More

> NHS sets out vision for IT-enabled, research-facilitating future. Article

Animal Health News

> High-flying Heska talks up business overhaul at NYC investor event. More

> Phibro updates guidance for the year, declares quarterly dividend. Report

> Kindred's losses expand as struggling startup boosts R&D efforts. Story

> FDA continues crackdown on equine drugmakers. Item

> Aratana shares sag despite lower-than-expected Q3 loss. Article

And Finally... A growing number of infections in Europe are evading even the most powerful, last-resort antibiotics. More

Suggested Articles

Horizon Therapeutics has notched an FDA approval for its rare eye disease med Tepezza (teprotumumab), a possible blockbuster drug in the making.

Eli Lilly has a pipeline stuffed with a host of assets and has decided it needs a new injectable drug and device plant to manufacture some of them.

After Clovis’ Rubraca snagged an FDA boost in prostate cancer last week, AZ and Merck’s rival Lynparza has matched it with a boost of its own.